Back to the Top
The following message was posted to: PharmPK
Dear All,
I have some queries regarding the EMEA guidlines on "Modified release
oral and Transdermal dosage forms".
In the section 4.1.2 Variability of the above mentioned guidline it is
stated that
"It may be valuable to assess the intra-individual variability. This
could be achieved by either repeated measurement of the concentration
profile at steady state or by performing a single dose study with
replicate design."
Now my questions are
1) How repeated measurement of concentration profile at steady state can
be done.
2) How intra-individual variability can be measured by repeated
measurement of concentration profile at steady state as mentioned in
guideline. Please provide some detail regarding its statistical aspect.
3) What should be the appropriate study design in above case?
Waiting for your invaluable replies.
Thanks & Regards,
Ravi Shankar Pandey
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "EMEA guidlines on Modified release oral dosage forms" as the subject | Support PharmPK by using the |
Copyright 1995-2011 David W. A. Bourne (david@boomer.org)